|
|
|
|
|
|
|
|
|
|
Super Quote | Detail Quote | Interactive Chart | Transaction | Related News | Related Securities | Company Information | Dividend Records | Short Sell
00460 SIHUAN PHARM
Nominal 
0.720 +0.010 (+1.408%) | 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Turnover | 1,860,539 | -14.701% | 2,181,189 | 3,291,270 | 2,464,226 | 2,886,979 |
| Cost of Sales | (564,895) | -18.557% | (693,608) | (842,754) | (549,777) | (592,052) |
| Gross Profit | 1,295,644 | -12.903% | 1,487,581 | 2,448,516 | 1,914,449 | 2,294,927 |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | ||
| Change in FV & Impairment on Inv. Prop. | -- | -- | -- | -- | -- | (276,464) | |
| Change in FV & Impairment on Others | -- | -- | (1,727,119) | (131,297) | -- | (3,695,039) | |
| Profit / (Loss) on Disposal | -- | -- | -- | 59,228 | -- | -- | |
| Other Non-operating Items | -- | -- | -- | -- | 72,307 | -- | |
| Share of Results of Asso. & JCEs | (53,621) | -33.699% | (80,875) | (158,581) | (13,064) | (7,190) | |
| Profit / (Loss) before Taxation | (161,260) | -92.403% | (2,122,778) | 486,049 | 765,844 | (2,466,923) | |
| Taxation | (96,427) | -51.001% | (196,794) | (253,279) | (219,040) | (290,388) | |
| Profit / (Loss) from Discontinued Operations | -- | -- | 36,296 | -- | (34,917) | -- | |
| Non-controlling Interests | 203,670 | -44.709% | 368,358 | 183,739 | (38,505) | 3,979 | |
| Others | -- | -- | -- | -- | -- | -- | |
| Profit / (Loss) Attributable to Shareholders | (54,017) | -97.179% | (1,914,918) | 416,509 | 473,382 | (2,753,332) | |
| 2023/12 - Final RMB(K¥) | %Chg (Compare to Final) | 2022/12 RMB(K¥) | 2021/12 RMB(K¥) | 2020/12 RMB(K¥) | 2019/12 RMB(K¥) | |
| Net Finance Costs / (Income) | 121,429 | 88.607% | 64,382 | (44,637) | (127,511) | (164,875) |
| Depreciation & Amortisation | 79,735 | -19.581% | 99,150 | 301,463 | 265,225 | 354,697 |
| Directors' Emoluments | 18,497 | 3.122% | 17,937 | 26,895 | 24,153 | 22,796 |
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| Auditor's Opinion Status | Unqualified | -- | Unqualified | Unqualified | Unqualified | Unqualified |
Market Valuation Indicators
| 2023/12 - Final | %Chg (Compare to Final) | 2022/12 | 2021/12 | 2020/12 | 2019/12 | |
| EPS (cts) | -0.580 | -97.173% | -20.520 | 4.420 | 5.000 | -29.100 |
| DPS (cts) | 0.000 | -- | 6.500 | 10.800 | 15.000 | 1.700 |
| Dividend Payout Ratio (%) | -- | -- | -- | 244.344% | 300.000% | -- |
| Cash flow per share ($) | 0.021 | -- | 0.005 | 0.071 | 0.024 | 0.150 |
| NBV per share ($) | 0.475 | -- | 0.508 | 0.888 | 0.971 | 1.015 |
| Remarks: | Real time quote last updated: 13/11/2024 16:13 |
| Real-time basic market prices of Hong Kong securities are provided by HKEx; a Designated Website authorized by the HKEx Group to provide the Service. | |
| Profit / (Loss) Attributable to Shareholders (¥) | RMB -33,424,000 |
| %Change | -32.673% |
| EPS / (LPS) | RMB -0.004 |
| NBV Per Share (¥) | RMB 0.474 |